Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | FAAH | O00519 | 8/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 5/20 | 0.32 |
| ▸ | FDPS | P14324 | 4/20 | 0.32 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25802040 | 0.98 | CES2 (0.42) | CES2LPAR1LPAR3TSHRFAAH | |
| SCHEMBL12886418 | 0.81 | — | — | |
| SCHEMBL1326585 | 0.79 | TSHR (0.39) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL23700088 | 0.77 | TSHR (0.42) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL23700067 | 0.77 | TSHR (0.42) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL23700072 | 0.77 | TSHR (0.42) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL16672477 | 0.77 | TSHR (0.42) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL9280150 | 0.76 | TSHR (0.41) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL834209 | 0.75 | CES2 (0.43) | CES2LPAR1LPAR3FAAHCES1 | |
| SCHEMBL11873392 | 0.74 | TSHR (0.39) | CES2LPAR1LPAR3TSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363912-B1 | SUBSTITUTED IMIDAZOTRIAZINONES | BAYER HEALTHCARE AG (DE) | 2006-05-24 | — | — | EP | disclosed |
| US-6998402-B2 | Substituted imidazotriazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2006-02-14 | — | — | US | disclosed |
| EP-1347978-B1 | NOVEL SUBSTITUTED IMIDAZOTRIAZINONES AS PDE II-INHIBITORS | BAYER HEALTHCARE AG (DE) | 2005-08-31 | — | — | EP | disclosed |
| US-20050009822-A1 | Novel substituted imidazotriazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2005-01-13 | — | — | US | disclosed |
| EP-1363912-A1 | NOVEL SUBSTITUTED IMIDAZOTRIAZINONES | Bayer Aktiengesellschaft (DE) | 2003-11-26 | — | — | EP | disclosed |
| EP-1347978-A1 | NOVEL SUBSTITUTED IMIDAZOTRIAZINONES AS PDE II-INHIBITORS | Bayer Aktiengesellschaft (DE) | 2003-10-01 | — | — | EP | disclosed |
| US-6573263-B2 | For improving perception, concentration power, learning power and/ or memory power | BAYER AKTIENGESELLSCHAFT (DE) | 2003-06-03 | — | — | US | disclosed |
| US-20020198377-A1 | Substituted imidazotriazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2002-12-26 | — | — | US | disclosed |
| WO-2002068423-A1 | NOVEL SUBSTITUTED IMIDAZOTRIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-09-06 | — | — | WO | disclosed |
| WO-2002050078-A1 | NOVEL SUBSTITUTED IMIDAZOTRIAZINONES AS PDE II-INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009822-A1 | Novel substituted imidazotriazinones | CAMK4, CALM1, IPO4 | CES2 2443/4885LPAR1 3286/4885LPAR3 2995/4885 |
| US-20020198377-A1 | Substituted imidazotriazinones | CAMK4, ITPR1, KCNJ5 | CES2 3164/4885LPAR1 2372/4885LPAR3 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.